Whalesbook
India's Pharma Ambition: Budgetary Reforms for Affordable Medicines
India's vibrant pharmaceutical market, already valued at $55 billion in 2025 and projected to surge to $120-130 billion by 2030, stands at a critical juncture. The sector, lauded for its resilience, now faces the dual challenge of fostering innovation while ensuring medicines remain affordable for its vast population. To sustain its growth trajectory and solidify its "pharmacy of the world" status, strategic budgetary interventions are deemed essential.
The Drive for Affordability and Innovation
The NITI Aayog's discussion paper highlights the imperative for reimagining India's research and development capabilities. A key focus for the industry must be on diseases that disproportionately affect large segments of the Indian population, even if they are not global priorities. This requires sustained policy continuity and effective implementation of R&D strategies, coupled with significant investment in technology for both research and market outreach.
Innovation Benefits and Tax Reforms
To spur innovation, particularly in areas relevant to Indian health needs, government support is crucial. EY India suggests that budgetary allocations could include research-linked incentives to fully cover expenses in government-identified priority areas. A significant proposal involves relaxing the patent-box tax regime.
This regime, designed to encourage R&D, should extend beyond patents registered solely in India. It needs to encompass income from foreign filings and registrations worldwide. Benefits should cover all patent-related income streams, including royalties and sales of patented rights or products. Concessional tax rates should apply to Indian registered patents, even if filed internationally. Furthermore, the current 75% domestic expenditure rule for such benefits could be relaxed to 51% or removed entirely when Indian residents bear all costs using global services.
R&D and Foreign Funding Incentives
Specific R&D incentives are proposed to enhance competitiveness for new chemical and biological entities. A 200% weighted deduction for companies undertaking such research is suggested. For foreign funding, a critical component for scaling up operations and R&D, extending the sunset clause for concessional tax on foreign borrowings would maintain an attractive investment route. Offering a weighted deduction of 150% on interest paid to foreign lenders could also reduce borrowing costs and stimulate overseas investment into India's pharma sector.
Manufacturing and Infrastructure Boost
To encourage domestic manufacturing and investment across the health sciences spectrum—including pharmaceuticals, biologics, medical devices, and equipment—a concessional tax regime of 15% alongside Profit Linked Incentives (PLI) is recommended. This would foster local production and technological advancement.
Addressing the high capital expenditure strain on hospitals and diagnostic centres is also vital. Inefficient infrastructural costs directly impact individual healthcare expenditure. Introducing PLI for healthcare infrastructure investment could attract private and foreign capital, making facilities more state-of-the-art and ultimately reducing the financial burden on patients.
Regulatory Clarity and Tax Treatment
The article also calls for clearer regulations governing interactions between pharmaceutical companies and healthcare professionals (HCPs). Standardized policies would provide much-needed certainty. A specific point of clarification is sought regarding the tax treatment of free samples distributed to doctors for efficacy assessment. These are professional tools, not personal benefits.
Additionally, the current system where companies face higher tax deductions (TDS) when doctors do not share their Permanent Account Number (PAN) creates operational challenges. Introducing a lower tax rate in such specific instances could ease cash flow issues and support the sector's growth.
Customs Duty and GST Adjustments
The pharmaceutical sector anticipates continued or expanded customs duty exemptions on imported raw materials and life-saving drugs. A rollback of the health cess on critical medical devices is also a key demand to reduce consumer costs. Lowering customs duties on imported diagnostic equipment and adjusting high Goods and Services Tax (GST) rates on lab supplies are further suggestions to bolster R&D investments and improve accessibility.
Impact
The proposed budgetary interventions aim to significantly lower the cost of medicines for Indian citizens, enhance the country's R&D capabilities, and strengthen its position as a global pharmaceutical manufacturing hub. This could lead to increased private and foreign investment, job creation, and improved public health outcomes. The measures, if implemented, could boost the revenue and profitability of Indian pharmaceutical companies by reducing operational costs and incentivizing innovation and manufacturing. The overall impact on the Indian stock market could be positive, with potential gains in the healthcare and pharmaceutical indices.
Impact Rating: 9/10
Difficult Terms Explained
- NITI Aayog: A policy think tank of the Government of India, responsible for shaping India's reform agenda.
- Atmanirbhar Bharat: A Hindi term meaning "self-reliant India," a vision for boosting domestic production and reducing import dependence.
- Patent-box tax regime: A tax regime that offers lower tax rates on profits derived from patented intellectual property.
- New chemical entities (NCEs) / New biological entities (NBEs): Novel drugs that have not been previously approved or marketed.
- Weighted deduction: A tax deduction where a certain percentage of expenditure is allowed as a deduction, often more than 100% of the actual expense.
- Sunset clause: A provision in a law or agreement that states the law or agreement will automatically be terminated after a certain date unless extended.
- Profit Linked Incentives (PLI): A scheme by the Indian government to provide financial incentives to companies for increasing their domestic production.
- Healthcare professionals (HCPs): Medical practitioners, nurses, pharmacists, and other healthcare workers involved in patient care.
- Tax Deducted at Source (TDS): A tax collected at the source of income by the payer on behalf of the government.
- Permanent Account Number (PAN): A unique 10-digit alphanumeric identifier issued by the Income Tax Department for tax purposes.
- Goods and Services Tax (GST): A comprehensive indirect tax levied on the supply of goods and services in India.